Travis Steed
Stock Analyst at B of A Securities
(2.76)
# 1,768
Out of 5,152 analysts
92
Total ratings
46.48%
Success rate
6.41%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Upgrades: Neutral | $15 → $30 | $22.63 | +32.57% | 3 | Feb 20, 2026 | |
| BBNX Beta Bionics | Maintains: Buy | $30 → $33 | $11.11 | +197.03% | 1 | Jan 5, 2026 | |
| PEN Penumbra | Maintains: Buy | $320 → $370 | $340.62 | +8.63% | 2 | Jan 5, 2026 | |
| BDX Becton, Dickinson and Company | Maintains: Neutral | $190 → $207 | $169.94 | +21.81% | 10 | Jan 5, 2026 | |
| CNMD CONMED | Maintains: Neutral | $65 → $52 | $41.40 | +25.60% | 5 | Dec 8, 2025 | |
| MASI Masimo | Initiates: Neutral | $162 | $175.46 | -7.67% | 1 | Nov 17, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $111.04 | +35.09% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $70.78 | +20.09% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $83.89 | +7.28% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $17.89 | +78.87% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $42 → $45 | $18.60 | +141.94% | 5 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $480 → $45 | $3.44 | +1,210.04% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $315 | $370.50 | -14.98% | 5 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $295 | $240.94 | +22.44% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $29.16 | -45.13% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $93.45 | +71.21% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $496.70 | -36.58% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.61 | +396.89% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $9.44 | +164.83% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $13.45 | +531.97% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $70.69 | +76.83% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $93.01 | +55.90% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $72.99 | -30.13% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $9.89 | +446.01% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $76.31 | -71.17% | 1 | Jul 17, 2017 |
Tandem Diabetes Care
Feb 20, 2026
Upgrades: Neutral
Price Target: $15 → $30
Current: $22.63
Upside: +32.57%
Beta Bionics
Jan 5, 2026
Maintains: Buy
Price Target: $30 → $33
Current: $11.11
Upside: +197.03%
Penumbra
Jan 5, 2026
Maintains: Buy
Price Target: $320 → $370
Current: $340.62
Upside: +8.63%
Becton, Dickinson and Company
Jan 5, 2026
Maintains: Neutral
Price Target: $190 → $207
Current: $169.94
Upside: +21.81%
CONMED
Dec 8, 2025
Maintains: Neutral
Price Target: $65 → $52
Current: $41.40
Upside: +25.60%
Masimo
Nov 17, 2025
Initiates: Neutral
Price Target: $162
Current: $175.46
Upside: -7.67%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $111.04
Upside: +35.09%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $70.78
Upside: +20.09%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $83.89
Upside: +7.28%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $17.89
Upside: +78.87%
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $18.60
Upside: +141.94%
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $3.44
Upside: +1,210.04%
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $370.50
Upside: -14.98%
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $240.94
Upside: +22.44%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $29.16
Upside: -45.13%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $93.45
Upside: +71.21%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $496.70
Upside: -36.58%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.61
Upside: +396.89%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $9.44
Upside: +164.83%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $13.45
Upside: +531.97%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $70.69
Upside: +76.83%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $93.01
Upside: +55.90%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $72.99
Upside: -30.13%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $9.89
Upside: +446.01%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $76.31
Upside: -71.17%